---
title: "Shouyao Holdings Co., LTD. (688197.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688197.SH.md"
symbol: "688197.SH"
name: "Shouyao Holdings Co., LTD."
industry: "Pharmaceuticals"
---

# Shouyao Holdings Co., LTD. (688197.SH)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | CN Market |
| Website | [www.shouyaoholding.com](https://www.shouyaoholding.com) |

## Company Profile

Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of innovative drugs in China. The company offers drugs for various indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroi...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:09.000Z

**Overall: C (0.45)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 132 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 119.88% |  |
| Net Profit YoY | 39.21% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 8.83 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5.78B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 8.67M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -17.61% | E |
| Profit Margin | -1486.39% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 119.88% | A |
| Net Profit YoY | 39.21% | B |
| Total Assets YoY | 0.00% | D |
| Net Assets YoY | -19.13% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -6.73% | D |
| OCF YoY | 119.88% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 0.00% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shouyao Holdings Co., LTD.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-17.61%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1486.39%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "119.88%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "39.21%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-19.13%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-6.73%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "119.88%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "0.00%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Allist (SH.688578) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (SZ.300573) | A | A | A | B | B | A |
| 03 | Hengrui Pharma (SH.600276) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (SZ.000538) | B | C | B | B | C | B |
| 05 | Salubris (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -27.95 | 190/222 | - | - | - |
| PB | 8.83 | 208/222 | 9.32 | 8.42 | 6.02 |
| PS (TTM) | 2697.33 | 222/222 | 2809.11 | 1311.99 | 1029.17 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-05-14T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 38.85 |
| Highest Target | 49.00 |
| Lowest Target | 49.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/688197.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688197.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688197.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.